|
APEC1621C
|
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 subprotocol of Tazemetostat in Patients with tumors Harboring Alterations in EZH2 or Members of the SWI/SNF Complex |
Not Open |
|
APEC1621B
|
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of JNJ-42756493 (Erdafitinib) in Patients with Tumors Harboring FGFR1/2/3/4 Alterations |
Open |
|
APEC1621D
|
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)-Phase 2 Subprotocol of LY3023414 in Patients with Solid Tumors |
Open |
|
APEC1621E
|
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Phase 2 Subprotocol of Selumetinib (AZD6244 Hydrogen Sulfate) in Patients with Tumors Harboring Activating MapK Pathway Mutations |
Open |
|
APEC1621G
|
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Phase 2 Subprotocol of Vemurafenib in Patients with Tumors Harboring Braf V600 Mutations |
Open |
|
APEC1621H
|
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Olaparib in Patients with Tumors Harboring Defects in DNA Damage Repair Genes. |
Open |
|
APEC1621I
|
NCI-COG Pediatric Match(MOLECULAR ANALYSIS FOR THERAPY CHOICE)-Phase 2 Subprotocol of Palbociclib in Patients with Tumors Harboring Activating Alterations in Cell Cycle Genes |
Open |
|
APEC1621J
|
NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)-Phase 2 Subprotocol of BVD-523FB (ulixerlinib) in Patients with Tumors Harboring Activating MAPK Pathway Mutations |
Open |
|
EAY131
|
Molecular Analysis for Therapy Choice (MATCH) |
Open |
|
HO07403
|
A Longitudinal Study to Evaluate Changes in Cellular Protein Expression and Activation in Bone Marrow Tumor Cells and Stromal Cells from Patients with Multiple Myeloma |
Open |
|
UW13056
|
Women's Integrative Sexual Health (WISH) Program Research Database |
Open |
|
UW14070
|
Phase 1, Open-Label, Dose Escalation Study of I-131-CLR1404 in Patients with Relapsed or Refractory Multiple Myeloma |
Open |
|
UW15106
|
Genomic Analysis of Long-Term Survivors with Metastatic Cancer |
Open |
|
UW16059
|
Patient-related Barriers to Pain Management: Revisiting the Pain Barriers Questionnaire |
Open |
|
UW16128
|
A global, prospective, non-interventional, observational study of presentation, treatment patterns, and outcomes in multiple myeloma patients-the INSIGHT-MM study
|
Open |
|
UW16139
|
A Pilot Study to Evaluate the Therapeutic Response of Tumor Cells Co-cultured with Non-tumor Cells from Patients with Multiple Myeloma ex vivo
|
Open |
|
UW16144
|
An Open-Label, Multicenter, Phase 2 Study of CLR 131 in Patients with Relapsed or Refractory (R/R) Select B-Cell Malignancies
|
Open |
|
UW17038
|
Direct Oral Anticoagulants (DOACs) versus LMWH +/- Warfarin for VTE in Cancer: A Randomized Effectiveness Trial (CANVAS Trial) |
Open |
|
UW17096
|
Improving Survivorship Care Planning for Bone Marrow Transplant Survivors: A Sociotechnical Systems Approach
|
Open |
|
UW17120
|
An Observational Study Profiling Biospecimens from Cancer Patients to Screen for Molecular Alterations (STRATA)
|
Open |
|
UW17136
|
A Phase 1, First-in-Man, Multicenter, Open-Label, Two Part Dose-Escalation and Cohort Expansion Study of Single-Agent GBR 1342 in Subjects with Previously Treated Multiple Myeloma
|
Open |
|
UW17147
|
Pre-Visit Planning in Palliative Care |
Open |
|
UW17156
|
Analysis of the Gut Microbiome in Patients Undergoing Autologous PBSCT and Lenalidomide Maintenance for Multiple Myeloma |
Open |
|
UW17157
|
A Phase 1b/2 Study of Selinexor (KPT-330) in Combination with Backbone Treatments for Relapsed/Refractory Multiple Myeloma |
Open |
|
UW18015
|
A Phase I/II Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects with Relapsed or Refractory Multiple Myeloma |
Open |
|
UW18025
|
Monoclonal Antibody-Based Sequential Therapy for Deep remission in Multiple Myeloma - MASTER TRIAL |
Open |
UW Carbone